Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC)
OwnerYi Zhu, Yiqian Wang +4inventors
InventorsYi Zhu, Yiqian Wang, Shi Zhuo, Jie Li, Yongguo Yu, Weili Wan
Life of this patent
Estimating the term…
Loading patent…
OwnerYi Zhu, Yiqian Wang +4inventors
InventorsYi Zhu, Yiqian Wang, Shi Zhuo, Jie Li, Yongguo Yu, Weili Wan
Estimating the term…
Disclosed in the present invention is a cysteine-modified antibody-toxin conjugate. The cysteine-modified antibody-toxin conjugate is characterized in that: the antibody is an antibody in which cysteine is inserted on a fixed point, and insertion sites of the cysteine comprising one or more of the following sites: a 110th site, a IIIth site and a 142th site of a light chain in a Kappa/λ light chain constant region, and a 254th site, a 255th site, a 258th, a 259th site, a 354th site, a 355th site, a 357th site, a 378th site, a 379th site, a 386th site, a 387th site or a 410th site of a heavy chain of a heavy chain constant region of an IgG antibody.
A cysteine-modified antibody-toxin conjugate, comprising an antibody and a cytotoxin, wherein the antibody comprises an inserted cysteine at one or more cysteine insertion sites at positions 110, 111, or 142 within the light chain constant region, or at positions 254, 255, 258, 259, 354, 355, 357, 378, 379, 386, 387 or 410 within the heavy chain constant region.
Dependencies are inferred from the claim text.